Virtual healthcare refers to the “virtual visits” that take place between patients and clinicians via technology – the visual and audio connectivity that allows “virtual” interactions to take place in real time, from practically any location. A videoconference between a doctor and a patient at home can be considered a virtual visit. Pharma companies have been collaborating with digital and data companies for some years to figure out how to effectively use virtual health and how it might improve processes throughout the business continuum. Virtual health technologies will allow the pharmaceutical sector to have a larger engagement with patients and clinicians across many touchpoints.
Title : Pathology and patient safety: The vital role of electronic medical record and pathology informatics in error reduction and precision medicine
Consolato M Sergi, University of Ottawa, Canada
Title : mRNA-based systemically delivered directed gene therapy using nanomaterials
A C Matin, Stanford University, United States
Title : Role of nanoformulations in treating Cystic Fibrosis
Bhupendra Gopalbhai Prajapati, Shree S.K.Patel College of Pharmaceutical Education and Research, India
Title : EU GMP annex1 barrier system and PIC/s annex 2A on cell and gene therapy
Richard Denk, SKAN AG, Switzerland
Title : Pro and con to dermpharm and tox assays- 2023
Howard I Maibach, University of California, United States
Title : Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Extracellular vesicles as delivery vehicles of therapeutic compounds
Stefania Raimondo, University of Palermo, Italy
Title : Pediatric brain on cannabinoids: Adverse effects of cannabinoid products in children and adolescents
Peter B Chase, Essentia Health- St. Mary's Medical Center, United States
Title : EBV latent membrane protein 1 augments gammer-delta T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules
Yue liu, Hong Kong Baptist University, China